| scholarly article | Q13442814 |
| P50 | author | Walter Kolch | Q30504262 |
| Owen J Sansom | Q37382476 | ||
| David Matallanas | Q39791128 | ||
| Fahd Al-mulla | Q42623473 | ||
| Matthias Drosten | Q52354858 | ||
| Piero Crespo | Q56380773 | ||
| P2093 | author name string | Mariano Barbacid | |
| Eric O'Neill | |||
| Colin Nixon | |||
| Waleed Al-Ali | |||
| David Romano | |||
| Brendan Doyle | |||
| P433 | issue | 6 | |
| P304 | page(s) | 893-906 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Molecular Cell | Q3319468 |
| P1476 | title | Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. | |
| P478 | volume | 44 |
| Q47670514 | A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer |
| Q35671176 | Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas |
| Q35349490 | Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer |
| Q34467580 | Cell cycle restriction is more important than apoptosis induction for RASSF1A protein tumor suppression |
| Q48238039 | Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors |
| Q35158033 | Competing to coordinate cell fate decisions: the MST2-Raf-1 signaling device |
| Q37716706 | Contribution of LATS1 and LATS2 promoter methylation in OSCC development |
| Q38911598 | Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design |
| Q35889525 | Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers |
| Q92932469 | Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D |
| Q27302367 | Functional role of Mst1/Mst2 in embryonic stem cell differentiation |
| Q37026412 | H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization |
| Q38004667 | Hippo signalling in the G2/M cell cycle phase: lessons learned from the yeast MEN and SIN pathways |
| Q51550959 | Hras helps hippo heterodimerize to evade tumor suppression. |
| Q38981572 | Identification of a ternary protein-complex as a therapeutic target for K-Ras-dependent colon cancer |
| Q90270715 | Investigation of the effect of P14 promoter aberrant methylation on the biological function of human lung cancer cells |
| Q37061204 | LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development. |
| Q92128564 | MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells |
| Q33821181 | MST1/MST2 Protein Kinases: Regulation and Physiologic Roles |
| Q53498705 | MST2-RASSF protein-protein interactions through SARAH domains. |
| Q92757939 | MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells |
| Q28548302 | Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation |
| Q30369861 | Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. |
| Q22001145 | Mst1 and Mst2 kinases: regulations and diseases |
| Q35213124 | Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer |
| Q47164988 | Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. |
| Q30370843 | NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2. |
| Q34389570 | Novel somatic mutations to PI3K pathway genes in metastatic melanoma |
| Q40885761 | Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. |
| Q47256433 | Oncogenic Ras Isoforms Signaling Specificity at the Membrane |
| Q38238612 | One Hippo and many masters: differential regulation of the Hippo pathway in cancer |
| Q24303432 | Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover |
| Q36116373 | Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. |
| Q42152409 | Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling |
| Q36371333 | Protein kinases of the Hippo pathway: regulation and substrates |
| Q89636636 | Pumping the brakes on RAS - negative regulators and death effectors of RAS |
| Q38009322 | RASSF Signalling and DNA Damage: Monitoring the Integrity of the Genome? |
| Q88595370 | RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis |
| Q38009323 | RASSF1A Signaling in the Heart: Novel Functions beyond Tumor Suppression |
| Q92811214 | RASSF1A Tumour Suppressor: Target the Network for Effective Cancer Therapy |
| Q91717152 | RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review |
| Q38956821 | RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2. |
| Q35242568 | Rare codons capacitate Kras-driven de novo tumorigenesis |
| Q37061781 | Ras and rheb signaling in survival and cell death |
| Q38862017 | Ras signaling through RASSF proteins |
| Q34517696 | Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation. |
| Q49853226 | Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway |
| Q35526111 | Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S. |
| Q51347935 | Reduced risk of apoptosis: mechanisms of stress responses. |
| Q38132299 | Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling |
| Q41609951 | Rheb may complex with RASSF1A to coordinate Hippo and TOR signaling |
| Q36808753 | Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis |
| Q90716816 | The Hippo pathway integrates PI3K-Akt signals with mechanical and polarity cues to control tissue growth |
| Q47817412 | The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation |
| Q39394211 | The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway |
| Q26744308 | The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair |
| Q91579024 | The Mystery of Rap1 Suppression of Oncogenic Ras |
| Q34968548 | The RASSF1A tumor suppressor regulates XPA-mediated DNA repair |
| Q39100434 | The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein. |
| Q39185488 | The differential effects of wild-type and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics |
| Q34490200 | The dynamic control of signal transduction networks in cancer cells |
| Q38898397 | The role of wild type RAS isoforms in cancer |
| Q37034046 | Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation |
| Q33778215 | Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response |
| Q54186255 | Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice. |
| Q33731697 | Wild-type RAS: keeping mutant RAS in CHK. |
| Q64081398 | experimental models account for higher complexity than preclinical settings in cancer |
| Q47850800 | p53 shades of Hippo. |
Search more.